NCT00537004 Language in Primary Progressive Aphasia
| NCT ID | NCT00537004 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Primary Progressive Aphasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2007-05 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2007-05 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary progressive aphasia * Right-handed * Native English speaker * Visual acuity of 20/30 corrected * Adequate hearing to follow conversation * Safe for an MRI scan Exclusion Criteria: * Left-handedness * Claustrophobia * Presence of significant medical illness that initially or in the future could interfere with continued participation in the study
Contact & Investigator
Marsel Mesulam, MD
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT00537004 clinical trial?
This trial is open to participants of all sexes, studying Primary Progressive Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00537004 currently recruiting?
Yes, NCT00537004 is actively recruiting participants. Contact the research team at PPA.Research@northwestern.edu for enrollment information.
Where is the NCT00537004 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT00537004 clinical trial?
NCT00537004 is sponsored by Northwestern University. The principal investigator is Marsel Mesulam, MD at Northwestern University. The trial plans to enroll 500 participants.